Canada markets close in 12 minutes

Intellia Therapeutics, Inc. (NTLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
47.26-0.45 (-0.94%)
As of 03:48PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close47.71
Open48.76
Bid46.33 x 800
Ask46.41 x 1300
Day's Range43.49 - 50.20
52 Week Range38.85 - 202.73
Volume947,222
Avg. Volume1,212,435
Market Cap3.585B
Beta (5Y Monthly)2.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

    Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose of NTLA-2001 resulted in rapid, deep and sustained reduction in disease-causing proteinInterim readout showed treatment with NTLA-2001 at 1.0 mg/kg dose led to 93% mean and 98% maximum serum TTR reduction by day 28, with durability observed through follow-up period; initiated Part 2 in the polyneuropathy arm, with plans to share additional d

  • GlobeNewswire

    Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

    CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. “We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer

  • GlobeNewswire

    Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

    Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapyFindings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of CD30-expressing hematologic cancers CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative the